The miRNA‐149‐5p/MyD88 axis is responsible for ursolic acid‐mediated attenuation of the stemness and chemoresistance of non‐small cell lung cancer cells

Chen, Quanfang; Luo, Jin; Wu, Cong; Lu, Huasong; Cai, Shuangqi; Bao, Chongxi; Li, Dongmei; Kong, Jinliang

doi:10.1002/tox.22891

Cited by 29 publications

(24 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the results showed that the overexpression of MDR1 could partially, but not completely, eliminate the regulatory effects of UA on Adriamycin resistance, which indicates that there are other molecular mechanisms and targets involved in UA‐mediated regulation on Adriamycin resistance. For example, the recent work indicates that UA attenuates paclitaxel resistance in non‐small cell lung cancer cells through inhibiting the miR‐149‐5p/MyD88 signaling 25 ; Consistently, UA reverses the paclitaxel resistance of breast cancer cells by targeting miR‐149‐5p/MyD88 26 ; And UA enhances the sensitivity of oxaliplatin in colorectal cancer by regulating reactive oxygen species production 9,27 . These results suggest that UA might regulate drug resistance through different mechanisms in different tumors.…”

Section: Discussionmentioning

confidence: 91%

Ursolic acid reduces Adriamycin resistance of human ovarian cancer cells through promoting the HuR translocation from cytoplasm to nucleus

Luo

Shi

et al. 2020

Environmental Toxicology

View full text Add to dashboard Cite

Ursolic acid (UA) has been shown to suppress various tumor progression, however, its roles in Adriamycin resistance of human ovarian cancer (OC) cells are still unclear. This work aims to investigate the effects of UA on the Adriamycin resistance of human OC cells. Here, we constructed Adriamycin‐resistant OC SKOV3‐Adr cells and found that UA attenuated Adriamycin resistance in SKOV3‐Adr cells. Additionally, UA enhanced Adriamycin sensitivity in the parental SKOV3 and another OC cell line A2780 cells. Mechanistic studies showed that HuR mRNA level was similar between SKOV3 and SKOV3‐Adr cells, but the cytoplasmic expression of HuR protein was increased in SKOV3‐Adr cells compared with that in SKOV3 cells, and subsequently enhancing the mRNA stability of multidrug resistance gene 1 (MDR1). Moreover, UA had no effects on HuR expression, but promoted the cytoplasm‐nucleus translocation of HuR protein, decreased MDR1 mRNA stability and thus reduced MDR1 expression. Furthermore, overexpression of MDR1 rescued the effects of UA on Adriamycin resistance and sensitivity. This work reveals a novel HuR/MDR1 axis responsible for UA‐mediated attenuation on Adriamycin resistance in OC cells.

show abstract

Section: Discussionmentioning

confidence: 91%

Ursolic acid reduces Adriamycin resistance of human ovarian cancer cells through promoting the HuR translocation from cytoplasm to nucleus

Luo

Shi

et al. 2020

Environmental Toxicology

View full text Add to dashboard Cite

show abstract

“…Moreover, ursolic acid (UA) inhibited the phosphorylation of the AKT/BAD signaling pathway in drug‐resistant OSCC cells, which in turn activated intrinsic apoptotic mechanisms [ 176 ]. Additionally, UA attenuated cancer cell stemness and thus reversed chemoresistance by interfering with miR‐149‐5p [ 177 ]. As such, drugs targeting ncRNAs hold potential in alleviating the drug resistance of OSCC.…”

Section: Ncrna‐centered Approaches To Mitigate Drug‐resistance Of Osccmentioning

confidence: 99%

The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential

Meng¹,

Lou

Yang³

et al. 2021

Cancer Communications

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC), the eighth most prevalent cancer in the world, arises from the interaction of multiple factors including tobacco, alcohol consumption, and betel quid. Chemotherapeutic agents such as cisplatin, 5‐fluorouracil, and paclitaxel have now become the first‐line options for OSCC patients. Nevertheless, most OSCC patients eventually acquire drug resistance, leading to poor prognosis. With the discovery and identification of non‐coding RNAs (ncRNAs), the functions of dysregulated ncRNAs in OSCC development and drug resistance are gradually being widely recognized. The mechanisms of drug resistance of OSCC are intricate and involve drug efflux, epithelial‐mesenchymal transition, DNA damage repair, and autophagy. At present, strategies to explore the reversal of drug resistance of OSCC need to be urgently developed. Nano‐delivery and self‐cellular drug delivery platforms are considered as effective strategies to overcome drug resistance due to their tumor targeting, controlled release, and consistent pharmacokinetic profiles. In particular, the combined application of new technologies (including CRISPR systems) opened up new horizons for the treatment of drug resistance of OSCC. Hence, this review explored emerging regulatory functions of ncRNAs in drug resistance of OSCC, elucidated multiple ncRNA‐meditated mechanisms of drug resistance of OSCC, and discussed the potential value of drug delivery platforms using nanoparticles and self‐cells as carriers in drug resistance of OSCC.

show abstract

“…Myeloid differentiation primary response 88 (MyD88) is responsible for cell survival, DNA repair, and maintenance of stemness, thereby contributing to therapeutic resistance in cancer [ 275 , 276 ]. It was disclosed that ursolic acid reverses paclitaxel resistance by downregulating MyD88 levels in lung and breast cancer [ 85 , 146 ]. These studies also confirmed that miR-149-5p is upregulated in ursolic acid-treated cells and negatively affects MyD88 levels ( Figure 3 and Table 4 ).…”

Section: Tumor-suppressive Mirnas Induced By Phytochemicals Currenmentioning

confidence: 99%

Participation of MicroRNAs in the Treatment of Cancer with Phytochemicals

et al. 2020

View full text Add to dashboard Cite

Cancer is a global health concern and one of the main causes of disease-related death. Even with considerable progress in investigations on cancer therapy, effective anti-cancer agents and regimens have thus far been insufficient. There has been compelling evidence that natural phytochemicals and their derivatives have potent anti-cancer activities. Plant-based anti-cancer agents, such as etoposide, irinotecan, paclitaxel, and vincristine, are currently being applied in medical treatments for patients with cancer. Further, the efficacy of plenty of phytochemicals has been evaluated to discover a promising candidate for cancer therapy. For developing more effective cancer therapy, it is required to apprehend the molecular mechanism deployed by natural compounds. MicroRNAs (miRNAs) have been realized to play a pivotal role in regulating cellular signaling pathways, affecting the efficacy of therapeutic agents in cancer. This review presents a feature of phytochemicals with anti-cancer activity, focusing mainly on the relationship between phytochemicals and miRNAs, with insights into the role of miRNAs as the mediators and the regulators of anti-cancer effects of phytochemicals.

show abstract

The miRNA‐149‐5p/MyD88 axis is responsible for ursolic acid‐mediated attenuation of the stemness and chemoresistance of non‐small cell lung cancer cells

Cited by 29 publications

References 23 publications

Ursolic acid reduces Adriamycin resistance of human ovarian cancer cells through promoting the HuR translocation from cytoplasm to nucleus

Ursolic acid reduces Adriamycin resistance of human ovarian cancer cells through promoting the HuR translocation from cytoplasm to nucleus

The role of non‐coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential

Participation of MicroRNAs in the Treatment of Cancer with Phytochemicals

Contact Info

Product

Resources

About